№ files_lp_3_process_9_43921
File format: docx Character count: 18399 File size: 90 KB
This document outlines the clinical practice and operational guidelines for the administration of rifapentine and isoniazid (INH) in the treatment of latent tuberculosis infection (LTBI), including criteria for use and monitoring protocols.
Year: 2024
Region / City: Canada
Subject: Latent Tuberculosis Infection Treatment
Document Type: Clinical Guideline
Author: Northern Regional Health Authority
Target Audience: Healthcare Providers, Clinical Care Teams
Action Period: 12 weeks (DOPT course)
Approval Date: July 15, 2014
Modification Date: Not specified
Clinical Area: Tuberculosis treatment
Monitoring Requirements: Yes
Treatment Method: Rifapentine and INH via DOPT
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two Phase 2 clinical trials
Year: 2021
Region / City: USA, Uganda, Vietnam
Topic: Pharmacokinetics of Rifapentine
Document Type: Supplementary Materials
Organization / Institution: Centers for Disease Control and Prevention, University of California San Francisco, University of Texas Health Science Center, and others
Authors: Radojka M. Savic, Marc Weiner, William Mac Kenzie, Melissa Engle, William C. Whitworth, John L. Johnson, Pheona Nsubuga, Payam Nahid, Nhung Viet Nguyen, Charles A. Peloquin, Kelly Dooley, Susan E. Dorman
Target Audience: Researchers, clinicians, health professionals
Date of Approval: Not provided
Date of Modifications: Not provided
Topics: Isoniazid LTBI Rifapentine